Z-VAD-FMK

For research use only.

Catalog No.S7023

535 publications

Z-VAD-FMK Chemical Structure

Molecular Weight(MW): 467.49

Z-VAD-FMK is a cell-permeable, irreversible pan-caspase inhibitor, blocks all features of apoptosis in THP.1 and Jurkat T-cells.

Size Price Stock Quantity  
USD 117 In stock
USD 470 In stock
USD 2570 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Z-VAD-FMK has been cited by 535 publications

Purity & Quality Control

Choose Selective Caspase Inhibitors

Biological Activity

Description Z-VAD-FMK is a cell-permeable, irreversible pan-caspase inhibitor, blocks all features of apoptosis in THP.1 and Jurkat T-cells.
Features A key compound for apoptosis studies.
Targets
Pan-caspase [1]
(THP.1, Jurkat T-cells)
In vitro

Z-VAD-FMK (10 mM) inhibits apoptosis in THP.1 cells. Z-VAD-FMK (10 μM) inhibits activation of PARP protease activity in control THP.1 cell lysates. Z-VAD-FMK (10 mM) inhibits the processing of CPP32 in intact THP.1 and Jurkat cells. [1] Z-VAD-FMK (50 μM) cotreatment abolishes the apoptotic morphology of camptothecin-treated HL60 cells. Z-VAD-FMK (50 μM) blocks camptothecin-induced DNA fragmentation in HL60 cells. [2] Z-VAD-FMK (50 μM) inhibits cell death following dSMN dsRNA-induced apoptosis in S2 cells. Z-VAD-FMK (50 μM) increases the percentage of transfected cells surviving from 26% to 63% in S2 cells. [3] Z-VAD-FMK (> 100 μM) enhances TNFα-induced neutrophil apoptosis, lower concentrations (1-30 μM) completely blocks TNFα-stimulated apoptosis in human neutrophils. [4] Z-VAD-FMK (10 mM) inhibits apoptosis in anterior stromal keratocytes. Z-VAD-FMK (10 mM) inhibits apoptosis in anterior stromal keratocytes detected with the TUNEL assay. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
GC1a NWXPXFNPSXCxcITvd4l{KEG|c3H5 MoWzOVDPxE1? NYHtcG1xOjSq NVLoV2FYcW6maXPheIV{KGFicILveIVkfGm4ZTDl[oZm[3RiYXfhbY5{fCCndH;wc5Nq\GV? NHy3UHYzPjF4OUC3OS=>
HGL5 NGPOSXdCeG:ydH;zbZMhSXO|YYm= MoLLOVDPxE1? NVLEOIZwOjSq NHLCc5BqdmSrY3H0[ZMh[SCycn;0[YN1cX[nIHXm[oVkfCCjZ3HpcpN1KGW2b4Dvd4ll\Q>? Ml3ZNlYyPjlyN{W=
HepG2 MnP3RZBweHSxc3nzJGF{e2G7 Ml\GNlDPxE1? MojyNYg> MlvjZZR1\W63YYTl[EB1cGViYYDvdJRwfGmlIHnu[JVkfGmxbjDv[kBKUUlvMUFCpC=> NWnh[ZkzOjZzNkS3PVU>
BEL-7402 MWTBdI9xfG:|aYOgRZN{[Xl? NFHsSIszOM7:TR?= MWSxbC=> M1;NNIF1fGWwdXH0[YQhfGinIHHwc5B1d3SrYzDpcoR2[3Srb36gc4YhUUmLLUGwxsA> NVTFbnNqOjZzNkS3PVU>
CEF MmDkT4lv[XOnIFHzd4F6 Mo\WNEw{Oyx4NzyxNFDPxE1? NV3DOHBvOTWvaX6= M4eyeoRwf25vcnXneYxifGW|IGDSJIVvgnmvZTDhZ5Rqfmm2eTD0c{A1OO,:hTDheEAyODEQvF2= NUOzW4tFOjZzMEKzN|k>
SP2/0 MXPBdI9xfG:|aYOgRZN{[Xl? MYmxNFDPxE1? MVWxbC=> NEDnOnpFVVOR MUHicI9kc3NidHjlJIFxd3C2b4Ppd{Bw\iCVUEKvNEBk\Wyucx?= NIPlOWEzPjB5NEezNi=>
HUVEC-2c MmH2RZBweHSxc3nzJGF{e2G7 M2jJOlUx|ryP MUK2bC=> MVrk[YNz\WG|ZXSgeIhmKG:6LVzEUE1qdmS3Y3XkJIF2fG:yaHHnfS=> MXSyOlAzOTd{OR?=
U1 NEX4eGlCeG:ydH;zbZMhSXO|YYm= NVnVUHQ1OC1zMEFOwG0> NYjuTnpqOmh? MVjy[YR2[2W|IHTyeYcucW6mdXPl[EBieG:ydH;zbZMh[W6mIIP1ZpNmeXWnboSgTGlXNTFicnXwcIlk[XSrb36gbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NXrEXW9nOjV7OEC5OFI>
ACH-2 NHPmNHZCeG:ydH;zbZMhSXO|YYm= NGD6[XQxNTJyMN88US=> Mlv4Nog> NGLO[JVz\WS3Y3XzJIRzfWdvaX7keYNm\CCjcH;weI9{cXNiYX7kJJN2[nOncYXlcpQhUEmYLUGgdoVxdGmlYYTpc44hcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MYeyOVk5ODl2Mh?=
U1 MUfLbY5ie2ViQYPzZZk> M1nWZVExOM7:TR?= NGPuUW4zcA>? MkTkbY5pcWKrdIOgZ4F{eGG|ZT2z NY[0b5h2OjV7OEC5OFI>
A549/V16 MoTIRZBweHSxc3nzJGF{e2G7 M4DqPVUx|ryP MXSxbC=> NI\1Snpz\XC{ZYPz[ZMhXEdxVF2tbY5lfWOnZDDhdI9xfG:|aYO= MknjNlU6PDZyM{O=
SGN MnX0RZBweHSxc3nzJGF{e2G7 M4W5RVIxdU1? MkTXOFhp MojEbIF{KG6xIHnu[ox2\W6lZTDvckBCUUZuIHPhcJBicW5iZYjwdoV{e2mxbjDvdkBk\WyuIHHwc5B1d3Orcx?= NX7BbGRZOjV6N{S2N|M>
HCT116  MUTBdI9xfG:|aYOgRZN{[Xl? MWi1NO69VQ>? MX2ybC=> MXTpcohq[mm2czD0bIUh[2WubDDk[YF1cCCrbnT1Z4VlKGK7IFTEWnA> M{j4eFI2QDZ6OEG4
DTK-SME M2nSOmFxd3C2b4Ppd{BCe3OjeR?= M1HtTVUx|ryP MYeybC=> NH\SdW5FVVOR Ml60dIFzfGmjbHz5JIlvcGmkaYTzJJRp\SCjcH;weI9{cXNiaX7keYNm\CCkeTDieZBqfmGlYXnu[S=> M3;yN|I2QDR|OEm3
HL-60 MmXIRZBweHSxc3nzJGF{e2G7 MkD5OVDPxE1? MkG2OFhp MVHy[YR2[2W|IHPlcIwh\GWjdHigZ4F2e2WmIHL5JHNMUS2LSTD0doVifG2nboVCpC=> NGTXOmQzPTh{NEC0Ny=>
U937 MoXLRZBweHSxc3nzJGF{e2G7 MYe1NO69VQ>? NUfjRopuPDiq M{jxZpJm\HWlZYOgZ4VtdCCmZXH0bEBk[XW|ZXSgZpkhW0uLLVnJJJRz\WG2bXXueOKh MWKyOVgzPDB2Mx?=
A549 NYLSdZZFSXCxcITvd4l{KEG|c3H5 M2[zcFIxKM7:TR?= MonPNlRp NX7KU4hwemWmdXPld{Bk\WyuIHTlZZRpKGOjdYPl[EBjgSCKRlPQJJRz\WG2bXXueC=> MlfsNlU4QTRzNEm=
HeLa Mn;XRZBweHSxc3nzJGF{e2G7 Mmn2NVDPxE1? NV\1[Jk{PDiq NUXzdmhw\GWlbHnu[ZMhfGinIILheIUhd2ZiYYDvdJRwe2m|IHTyZY1ifGmlYXzsfS=> MWiyOVc4OjV2NR?=
SGC-7901 MnLORZBweHSxc3nzJGF{e2G7 NVfyZ3NvOjEEoN88US=> M3fWSVFp MljrbY5pcWKrdIOgeIhmKGOnbHyg[IVifGhiaX7keYNm\CCkeTDvfIFtcXCuYYTpci=> M1fNVVI2PzZ5MEe2
MCF-7 M4PXTmFxd3C2b4Ppd{BCe3OjeR?= MmLPNVDPxE1? MoLQNog> M{S2UIlvcGmkaYTzJJRp\SClZXzsJIRm[XSqIHnu[JVk\WRiYomgN2I> Mn7LNlU4OjJzMUS=
A549 NU\nTlFqSXCxcITvd4l{KEG|c3H5 M{jkOVExKM7:TR?= NHn5TGMzPGh? MXHEUXNQ M{LGeJBzd22xdHXzJGhDSy22cnXheIVlKEF3NEmgZ4VtdCC|dYL2bZZidCBoIHH0eIVvfWG2ZYOgeIhmKGOuZXH2[YQhWEGUUDDlfJBz\XO|aX;u NWftUpdZOjV4OEO1Olg>
U87 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVm1NO69VQ>? M{C1d|Fp MX7y[YNwfmW{czDj[YxtKGe{b4f0bEBnem:vIGTNXkB1emWjdH3lcpQ> NHfaOlQzPTZ6MU[2PC=>
Neocortical Neuron NXnhWGkxVmW3cn;0c5hq[2m2eTDBd5NigQ>? MmXsNVAx|ryP MVKxbC=> MoTlZY51[Wexbnn6[ZMhUG:rYX3p[IUhSS2LbnT1Z4VlKE6ndYLveI95cWOrdIm= M1r6WFI2Pjd3MECx
Primary human placental cytotrophoblasts M2jkSWFxd3C2b4Ppd{BCe3OjeR?= M4\vfVMx|ryP MUWyOIg> M3\DNmROW09? NYTMW2VEemW4ZYLz[ZMhfGinIHnubIljcXSrb36gc4YhOTIQsj3IV2QzKGK7IITybYNtd3OjbtMg MUSyOVY1OjV7Mh?=
MM MUDBdI9xfG:|aYOgRZN{[Xl? NW\JOZh3PTEQvF2= NW\3b|ZKOjCvaX6= MUjwZZJ1dHliaX7obYJqfHNiU1jLMYlv\HWlZXSgJINmdGxiZHXheIg> M1fYcVI2PTNyMEm4
DLD1 MmrSRZBweHSxc3nzJGF{e2G7 MX2yNOKh|ryP NFzpSpgycA>? M4n0bZBienSueTDy[ZZmenOnczDj[YxtKGGyb4D0c5NqeyClYYXz[YQh[nliV2PQNS=> NGnndpkzPTV{NEK0Oi=>
MDA-MB-231 M365TGN6fG:2b4jpZ4l1gSCDc4PhfS=> NVTn[pVLOTEQvF2= NHG1cGoycA>? MVPheYdu\W62czDj[YxtKGSnYYToJIFnfGW{IFPIWWEhfHKnYYTt[Y51 M4fwflI2PTJzNUCx
MKN28 MnLIRZBweHSxc3nzJGF{e2G7 NF\TS4gyOM7:TR?= MkjpN|BucW5? MofHSG1UVw>? M1\weYlvcGmkaYTzJHRPTi4QsTDwcJV{KEOKWD3pcoR2[2WmIHHwc5B1d3Orcx?= MmDjNlU2OTN7NkC=
HL-60 MoXPR5l1d3SxeHnjbZR6KEG|c3H5 MoTQNVAx|ryP NFnNVWMycA>? M4HGXWROW09? Mm\zxsBqdXC{b4\ld{B3cWGkaXzpeJkhd2ZiVFPORZMufHKnYYTl[EBk\Wyucx?= MYiyOVUxOjl|Mh?=
AGS NXTmfpAxSXCxcITvd4l{KEG|c3H5 NGnIOG0yOM7:TR?= MVqxbC=> NETrPZVxemW4ZX70d{BkfXKldX3pck1qdmS3Y3XkJINt\WG4YXflJI9nKGOjc4Dhd4UuOyxiLUisJIFv\CBvOTDwdo91\Wmwcx?= MV:yOVQ6OjJzNB?=
A549  NEHYWm5CeG:ydH;zbZMhSXO|YYm= NF;UPYkyOM7:TR?= M3jVeVI1cA>? MnnXZoxw[2u|IFTNRXMucW6mdXPl[EBkdGWjdnHn[UBw\iClYYPwZZNmNTNiYX7kJHBCWlBiYX7kJIFxd3C2b4TpZ{Bk\WyuIHTlZZRp MmX5NlU1OzR7OEm=
INS-1 M3:4T2Fxd3C2b4Ppd{BCe3OjeR?= NGXDUYY2OM7:TR?= NIfyO2U3cA>? M{\QRWROW09? NF;CRWFl\WO{ZXHz[ZMhfGinIIDyc5BwenSrb36gc4Yh\WG{bImgZZBweHSxdHnjJINmdGy|wrC= M2jwdFI2PDNyOEm3
Primary hepatocytes  NXvocpVESXCxcITvd4l{KEG|c3H5 NVr5d|FtPTEQvF2= NETERWIyQGh? Mo\jbY5pcWKrdIOgZZBweHSxc3nzJI9nKGincHH0c4N6fGW|IHnu[JVk\WRiYomgRYN1KERiYX7kJHRPTi4QsR?= MWmyOVQxPzV|OB?=
L929-A  MXLDfZRwfG:6aXPpeJkhSXO|YYm= NWDuZndYOjEEoN88US=> NIT1ZWMzPGh? NXTKS2N7cW6qaXLpeJMhXE6IzsGtbY5lfWOnZDDj[YxtKGSnYYTo NXPmeWNqOjV|OUi1OFA>
L929-N NXi1U|RNS3m2b4TvfIlkcXS7IFHzd4F6 M1;qT|IxyqEQvF2= M3riT|I1cA>? Mnvz[Y5p[W6lZYOg[IVifGhidnnhJIF2fG:lcnnu[UBVVkcQsTDwdo9lfWO2aX;u MlTzNlU{QTh3NEC=
Cytotoxicity Assay NIHGTZVE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MVKyNO69VQ>? MmfaOFhp NWiz[WQ4eHKndnXueEBOUE2GLXnu[JVk\WRiY3XscEBl\WG2aB?= MU[yOVM6OjFzNh?=
COS7 NXjS[VN3U2mwYYPlJGF{e2G7 NEXCWZYyOM7:TR?= NUH1UnczOjSq NF[5TnVqdmO{ZXHz[ZMh[2G|cHHz[UA{NzdiYXP0bZZqfGmncx?= MYqyOVM5PDB{NR?=
COS7 NWDJWJJ4SXCxcITvd4l{KEG|c3H5 NHyySHAyOM7:TR?= NGq5bYo1QGh? MWnwZZJ1cWGubImgdJJmfmWwdHXkJGZEOTBzLXnu[JVk\WRiY3XscEBl\WG2aB?= MnX4NlU{QDRyMkW=
A375 NH6xd4hCeG:ydH;zbZMhSXO|YYm= M1[3SlMx|ryP MViybC=> NUPtRWVKeHKndnXueJMhfGinIHTyeYcucW6mdXPl[EBRSVKSIHPs[YF3[Wen MUSyOVM4PjFzNR?=
A549 MXjBdI9xfG:|aYOgRZN{[Xl? M3:zfVUx|ryP Mkf2NlRp NYrGdFBmemW4ZYLz[ZMhemmkb4PvcYUh[mmxZ3Xu[ZNqeyCjbnSgZZBweHSxc3nzJINifXOnZDDifUAhS2iran;u[4Ridg>? M2noNFI2OzR7N{ix
A549 M{noeWFxd3C2b4Ppd{BCe3OjeR?= MVKyMlUuOjYQvF2= MVixbC=> NWDxV3JD\GWlcnXhd4V{KHSqZTDwc5B2dGG2aX;uJI9nKGGyb4D0c5Rq[yClZXzsd{Bl\XCnbnSgc44h[2:wY3XueJJifGmxboO= M4n4TFI2OzR{NEK3
 NBL-W-S  Mk\uRZBweHSxc3nzJGF{e2G7 NU\r[nY{PTEQvF2= Mnm5NYg> MmDD[pVtdHlicnXzZ5VmeyClZXzsJJZq[WKrbHn0fUBi\nSncjDHRW5VNTZzIITy[YF1dWWwdB?= MoXrNlU{OjN{MkK=
Caki-1  M{HtbmFxd3C2b4Ppd{BCe3OjeR?= NF\ze|k1OM7:TR?= NIfVdm41QGh? M1vQTpJm\HWlZYOgeIhmKG63bXLldkBw\iCDbn7lfIlvKFZvcH;zbZRqfmViY3XscJM> NILjSoozPTJ5OUG5NS=>
769-P NY\sZ3ZvSXCxcITvd4l{KEG|c3H5 NInNcXc1OM7:TR?= MVG0PIg> NY\QcWFOemWmdXPld{B1cGViboXtZoVzKG:oIFHucoV5cW5iVj3wc5NqfGm4ZTDj[Yxtew>? M4jke|I2Ojd7MUmx
H9c2 NHnF[ZpCeG:ydH;zbZMhSXO|YYm= MoLPOVDPxE1? MmXPNYg> MUfpcohq[mm2czDEU3gucW6mdXPl[EBk[XOyYYPlJFMh[WO2aY\heIlwdiCkdYSgco91KHSqZTDsc5N{KG:oIHPlcIx{ NWTXU4VlOjV{OEO4NVk>
K562 M4TnSGFxd3C2b4Ppd{BCe3OjeR?= NYTXTIxoPTEQvF2= NYf4UnhyPGh? NGD2NphqdmirYnn0d{BL[WNvQT3pcoR2[2WmIHPlcIwh[XCxcITvd4l{ MUWyOVI1OTZzOR?=
L929 NYqzSGhtSXCxcITvd4l{KEG|c3H5 NXPDcIxnOTEQvF2= MUW2bC=> M33RN4lv\HWlZYOgcoVkem:ydH;zbZMhf2m2aDDUUmY> M4rFeVI2OTl3Nk[w
A549 MWrBdI9xfG:|aYOgRZN{[Xl? NHvHWWYyOM7:TR?= MmPzN4g> Mn75doVlfWOnczDj[YxtKGGyb4D0c5NqeyClYYXz[YQh[nliUGHR MonlNlUyPjF4OUm=
MCF-7 NF76[WVCeG:ydH;zbZMhSXO|YYm= MlPENlDPxE1? NIfWeHQzcA>? NFmzTGtl\WO{ZXHz[ZMhU0SULYPpVm5CNWmwZIXj[YQh[XCxcITvd4l{ NGnqc|czPTF6MkK0NC=>
OS MoDJRZBweHSxc3nzJGF{e2G7 NH3kcmQzOC92MN88US=> MXK3Nog> M{C1SolvcGmkaYTzJG9UKGOnbHygeoli[mmuaYT5JJJm\HWldHnvckBjgSCFNjDj[ZJidWmmZR?= NHHYNoMzPTF3MkO5PS=>
HUVECs NILWS2VCeG:ydH;zbZMhSXO|YYm= M361flEx|ryP NH\VZoUzcA>? M4ftTOKhcW6qaXLpeJMh[XCxcITvd4l{KGGwZDDmZYNqdGm2YYTld{BifXSxcHjh[5khcW5iRFXOWlIucW6oZXP0[YQhUFWYRVPz NEnXT3ozPTF|OEewNy=>
EA.hy926 MojTRZBweHSxc3nzJGF{e2G7 NX22WWk6OTEQvF2= M3;CcFJp NULuV3FOyqCrbnjpZol1eyCjcH;weI9{cXNiYX7kJIZi[2muaYTheIV{KGG3dH;wbIFogSCrbjDESW5XOi2rbn\lZ5Rm\CCHQT7ofVkzPg>? MmfJNlUyOzh5MEO=
Ebs Mlz0RZBweHSxc3nzJGF{e2G7 MmrZNVAuOTByzszN MkPMNlRp M3\wNuKhVU2WUzDn[Y5memG2aX;uJJJifGViZHXjdoVie2WmIHHzJJRp\SClb37j[Y51emG2aX;uJI9nKHpvVlHEMoZucyCrbnPy[YF{\WR? MkGyNlUyOzR6MUe=
Jurkat M2\FN2Fxd3C2b4Ppd{BCe3OjeR?= Mlj1NlDPxE1? MXKyOIg> Mk[5SG1UVw>? M1foXpBienSrYXzsfUBqdmirYnn0JINmdGxiZHXheIghd2ZiSoXyb4F1KGOnbHzzJIlv\HWlZXSgZpkhOTByNUitSlQh[2:vYnnu[YQhf2m2aDDWVGHDqA>? NFPpUmUzPTF{MEeyNy=>
K562 MXfBdI9xfG:|aYOgRZN{[Xl? NYDkbnR5OC5zLUJOwG0> MVqxbC=> MoDPbY5pcWKrdIOgZ4xm[X[jZ3Wgc4YhUFOSOUCgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= MoT3NlUyOTlzOEi=
IMR-32 NITEVXFCeG:ydH;zbZMhSXO|YYm= MVK0NOKh|ryPwrC= M1\HUVJp M2nhbIRm[3KnYYPlJIlvKGGyb4D0c5Rq[yClZXzsd{Bkd22yYYLl[EB1dyCWLUKgeI95cW5? MWSyOVA5PDd3NR?=
RPMI 8226 Mln6RZBweHSxc3nzJGF{e2G7 NY\pVFZ4OTByzszN MXOxbC=> M3[2doFtdW:|dDDjc41xdGW2ZXz5JIJtd2OtczDj[YxtKGSnYYToJINifXOnZDDifUBv\WO{b4P0ZZRqdi1z MUKyOVA{Pzh3MR?=
U266  MYrBdI9xfG:|aYOgRZN{[Xl? M{XQZVExOM7:TR?= NWe5XoxWOWh? M{TPdpBienSrYXzsfUBjdG:la4OgZ4VtdCCmZXH0bEBk[XW|ZXSgZpkhdmWlcn;zeIF1cW5vMR?= MlfpNlUxOzd6NUG=
H929  M3PKOWFxd3C2b4Ppd{BCe3OjeR?= MnrTNVAx|ryP M3fsUlFp Mo\hdIFzfGmjbHz5JIJtd2OtczDj[YxtKGSnYYToJINifXOnZDDifUBv\WO{b4P0ZZRqdi1z MXOyOVA{Pzh3MR?=
MM.1S  NEjGNWlCeG:ydH;zbZMhSXO|YYm= MnTBNVAx|ryP NXTKTHNOOWh? NYXHS3NO\W[oaXPp[Y51dHlicILleoVvfHNic3;yZYZmdmmkLXnu[JVk\WRiY3XscEBl\WG2aDDjc41jcW6nIIfpeIghdmWlcn;zeIF1cW5vMR?= MXqyOVA{Pzh3MR?=
C6 NUnIWWJDSXCxcITvd4l{KEG|c3H5 MWG1NO69VQ>? M2HK[VQ5cA>? MXHwdoV3\W62czD0bIUhdG:|czDv[kBk\WyuII\pZYJqdGm2eTDjZZV{\WRiYomgdJJm\26nbn;sc45m MUSyOVAyOzR5OR?=
AGS NXqxUnBvSXCxcITvd4l{KEG|c3H5 MlSzOVDPxE1? NVmxeWltOjSq MlexZYJwdGm|aIOg{tIudGGyYXPoc45mNWmwZIXj[YQh[2WubDDk[YF1cCCjbnSgbY5pcWKrdHXkJIdzd3e2aB?= NGH4[pQzPTByOU[5PC=>
HeLa  NHKxV3ZCeG:ydH;zbZMhSXO|YYm= NWHSNWpFPDEQvF2= NHf6b2wzPGh? MWPpcohq[mm2czD0bIUhcW6lcnXhd4VlKGGyb4D0c5NqeyCrbnT1Z4VlKGK7IIPpVm5HOTJz NEDrU2UzPDl{OE[4OS=>
THP-1  M1jKSWFxd3C2b4Ppd{BCe3OjeR?= NGLNNIkyOM7:TR?= Ml;HNYg> Mn2ydoVlfWOnczDhdI9xfG:|aYOgbY5lfWOnZDDifUBCVEFvU1TUxsA> Mm[0NlQ6OjN4NUO=
P815  MYrBdI9xfG:|aYOgRZN{[Xl? MVSxNFAhyrWP NF\LcGcyOmh? MnfkSG1UVw>? MWHpcohq[mm2czD2bZJ2ey2rbnT1Z4VlKGGyb4D0c5Nqew>? NFWyN5IzPDl{M{K3Ny=>
HCT116 Mn;FRZBweHSxc3nzJGF{e2G7 M{fyZlIx|ryP M3q0S|I1cA>? MXnhZpJw\2G2ZYOgc4YhXFFvaX7keYNm\CCjcH;weI9{cQ>? MlTRNlQ5QTB2NEm=
SW1116  MXPBdI9xfG:|aYOgRZN{[Xl? M3G5R|ExKML3TR?= NIe4dowycA>? NWPlXJB7TE2VTx?= MWjy[ZN1emGrboOgZ4VtdCCjcH;weI9{cXNiaX7keYNm\CCkeTDn[YZqfGmwaXKgdIx2eyCmZXPpeIFjcW6n NEHjUIczPDh5NEK4Oi=>
LOVO NH\2[I1CeG:ydH;zbZMhSXO|YYm= M{D3dFExKML3TR?= MlHSNYg> NYjTPHZJTE2VTx?= M1voeJJme3S{YXnud{Bk\WyuIHHwc5B1d3OrczDpcoR2[2WmIHL5JIdm\mm2aX7pZkBxdHW|IHTlZ4l1[WKrbnW= MnzrNlQ5PzR{OE[=
SNU449  MkT6RZBweHSxc3nzJGF{e2G7 NFPpbpgzOM7:TR?= NUjzOWtuPDiq MlnNSG1UVw>? NHzib2tl\WO{ZXHz[ZMhdWmULUS1NU1qdmS3Y3XkJIFxd3C2b4TpZy=> NHnMdokzPDh2MU[zPC=>
Caco-2 NYLHNohUSXCxcITvd4l{KEG|c3H5 NEHLc4U1OOLCid88US=> M{juVVRp M17S[ZBz\X[nboTzJHNVNTdvaX7keYNm\CCcTz2xJINp[W6pZYOgZY5lKFSHUjDkdo9x Mom5NlQ5OjJzOEO=
macrophage NV;SWpRDS2WubDDWbYFjcWyrdImgRZN{[Xl? MYqwMVIxOM7:TR?= NF7jSG4zPGh? NGD6[4FqdmS3Y3XzJHRPTi1iYX7kJHJqeDNvZHXw[Y5l\W62IH7lZ5JweHSxc3nzJIlvKG2jY4LvdIhi\2V? MWmyOFc6QTV4NR?=
AGS  MYjBdI9xfG:|aYOgRZN{[Xl? MV:yNO69VQ>? NXzuSXVMOTKq M1;LO2ROW09? NV\LdoZQemWmdXPld{B1cGViaX7keYN1cW:wIH;mJIFxd3C2b4Ppd{BqdiC{ZYPwc45{\SC2bzD0bIUhTXSRQXOg[pJi[3Srb36gbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NGL3bIszPDd6OUewNy=>
LCC9  NHPIeI1E\WyuIG\pZYJqdGm2eTDBd5NigQ>? MYixNFDPxE1? MlKxOYQ> NUDVbWVP[myxY3vzJINmdGxiZHXheIghcW6mdXPl[EBjgSClb33ibY5ifGmxbjDMNVch[W6mIHPocI9zd3G3aX7l MX6yOFc5PTJ3Nh?=
U937  NF3Kb2hv\WO{b4D0c5NqeyCDc4PhfS=> NHLybHMyOMLizszN MnXHN|DDqG2rbh?= NGroOIRqdmS3Y3XzJI5m[3KxcITvd4l{KGOxbXLpcoUhf2m2aDDUUmY> MkDVNlQ4PzN5NU[=
T cell MlHVR4VtdCCycn;sbYZmemG2aX;uJIF{e2G7 NHrRRVExNTFyMN88US=> M2Sy[lczcA>? M1TNR2lEPTB;N{Cg{txONCCrbnjpZol1eyCjboTpMWNFOy2rbnT1Z4VlKFRiY3XscEBxem:uaX\ldoF1cW:wIHnuJHBDVUO| NFHTOIUzPDd4OEewOy=>
HeLa  M13ifWFxd3C2b4Ppd{BCe3OjeR?= NUj0dXZWPTEQvF2= M1HOXFczcA>? M1TCSGROW09? Mlq2dJJmfmWwdIOgZZBweHSxc3nzJIlv\HWlZXSgZpkh[2:vcH;1coR{yqBz4pETOS=> Mnz3NlQ4PTR5OE[=
HeLa  MUDBdI9xfG:|aYOgRZN{[Xl? NXvhc21{OTByzszN NV6zWFloOjSq MYDzeZBxemW|c3XzJJJifGVib3[gZ4VtdCCmZXH0bEBqdmS3Y3XkJIJ6KG:4ZYLlfJBz\XO|aX;uJI9nKEd3OWOgc5IhTzdzUjDwNVUx\2y3ZXVCpC=> NYLCWmF7OjR5MkK0Olg>
IEC-6  MUfBdI9xfG:|aYOgRZN{[Xl? NHvKXXAyOM7:TR?= Ml7hNlRp Mn;qdJJmfmWwdIOgWINlSS2rbnT1Z4VlKGOjc4Dhd4UuOyClbHXheoFo\SCjbnSg{tIu[2G2ZX7pckBl\We{YXTheIlwdg>? M2rRNlI1PzFzNUex
HCT116 MX;BdI9xfG:|aYOgRZN{[Xl? MXuyNO69VQ>? NF\hcnMzPGh? M4LYTYlvcGmkaYTzJJRp\SClZXzsJIFxd3C2b4TpZ{BqdmS3Y3XkJIJ6KFmOVEKwOS=> NEXwTIszPDdzM{ixNi=>
L02 MVvBdI9xfG:|aYOgRZN{[Xl? MXmyNO69VQ>? M3TWVlFp NFvKU5lxemW4ZX70d{B1cGViY3XscEBieG:ydH;zbZMhcW6mdXPl[EBjgSCPRVjQ M1G2[FI1PzB4NE[x
A375 NXWyS4l6SXCxcITvd4l{KEG|c3H5 Mly3NlDPxE1? NInabGUzPGh? MkPNdoV3\XK|ZYOg[IlkcXS{aX7vcoUhSi2rbnT1Z4VlKGGyb4D0c5Nqew>? M2DOdVI1Pjl7MUGx
HDPC NIDYV3hCeG:ydH;zbZMhSXO|YYm= MX21NOK2VQ>? NWXSdGdxOjSq M3fJdolvcGmkaYTzJG5QNWmwZIXj[YQh[XCxcITvd4l{ MU[yOFY{PDV7Mx?=
A549 MnrQRZBweHSxc3nzJGF{e2G7 MWe1NOK2VQ>? Mmm5Nog> NHLz[3VFVVOR MYnwdoV3\W62czD0bIUhcHmyb3TpdIxwcWRiRF7BJINwdnSnboSgdIhie2ViaX7keYNm\CCkeTDj[ZBp[WyxY3jyc41qdg>? NIKxcFczPDV6OEGzOS=>
 BV-2 MkGxRZBweHSxc3nzJGF{e2G7 M33HbVIx|ryP NIf1TngzcA>? NYrnflFje3WycILld5NmeyCXVj3pcoR2[2WmIHPodo9u[XSrbjDlfJRzfXOrb36gZY5lKGSrbHH0bY9vKG:oIITo[UBvfWOuZXHyJIVvfmWub4Dl M{jaelI1PTV6MUG4
HT-29  MWfBdI9xfG:|aYOgRZN{[Xl? NVPOOFh[PTEQvF2= NEG4e3c1QGh? NFjVbWdjdG:la4OgeIhmKGGyb4D0c5NqeyCrbnT1Z4VlKGK7IHvh[Y1x\mW{b3y= M33KPVI1PTR7MUe1
A549 NWnEUWhKSXCxcITvd4l{KEG|c3H5 NHO0eFk2|ryP NY\yNYdSOjSq NHLvNWt{fXCycnXzd4V{KD[nwrCoRmsyODB2MDmtbY5lfWOnZDDhdI9xfG:|aYRCpC=> MVOyOFUzQTh5MR?=
MIA-PaCa-2 NULQWHJYSXCxcITvd4l{KEG|c3H5 NXfwNnFEOjSq NWTudJIx[myxY3vzJINt\WG4YXflJI9nKGOjc4Dhd4UuOyCrbnT1Z4VlKGK7IHLveIghSS12NEO2OVQh[W6mIIDhZ4xqfGG6ZXy= NXHxR4VMOjR3MUC5PVI>
Caki-1 MX3BdI9xfG:|aYOgRZN{[Xl? NG\SUogzOM7:TR?= M3q1OlFp MUTpcohq[mm2czDTR3AucW6mdXPl[EBieG:ydH;zbZM> NGfyZ5ozPDVyNE[4NS=>
CLL NUPJVnk2SXCxcITvd4l{KEG|c3H5 MkGwNlXPxE1? MkD5NYg> M{LV[JBienSrYXzsfUBjdG:la4OgUWxPOjJ|OD3pcoR2[2WmIHPlcIwh[XCxcITvd4l{ NWHNXZZMOjR2Nke2N|Q>
SGC-7901 NUXGNWFtSXCxcITvd4l{KEG|c3H5 MXqxNO69VQ>? NIHEZ3IzPGh? M3H1bJBzd22xdHXzJJRp\SCFR1nJMYlvcGmkaYTl[EBk\WyuIHfyc5d1cCCrbjDTS2MuPzlyMTDj[Yxtew>? MX6yOFQ2PDR6OB?=
k1735 MYTBdI9xfG:|aYOgRZN{[Xl? M2PWWVIx6oDLzszt M2S5eFRp MWDpcohq[mm2c9MgV4FtdW:wZXzsZU1qdmS3Y3XkJIFxd3C2b4Ppdy=> NGSxWJczPDR3MUGxOi=>
HaCaT  MWTBdI9xfG:|aYOgRZN{[Xl? M{XEWlExOM7:TR?= M4H6ZVFp NFToWYljdHWwdIOgWXZDNWmwZIXj[YQh[XCxcITvd4l{KGmwIFjhR4FVKGOnbHzz M4TLVFI1OzV4OUm3
podocytes M1ixZWFxd3C2b4Ppd{BCe3OjeR?= NET6VZUzODEQvF2= M4PC[|Zp MYDpcohq[mm2czDhdI9xfG:|aYOgbY5lfWOnZDDifUA{NDRvRFfF M4W2elI1OzN5N{e3
 KB NELYUm9CeG:ydH;zbZMhSXO|YYm= NGrvW3Y2OM7:TR?= M{DJWFI1cA>? MX7pcohq[mm2czDMbYNwNUFvaX7keYNm\CClYYPwZZNmNTNiYX7kJHBCWlBiYXP0bZZifGmxbh?= MnvCNlQ{Ozd2OUK=
 HepG2  MVjBdI9xfG:|aYOgRZN{[Xl? MWqxNO69VQ>? NEDLWIczPGh? MoTKdoVlfWOnczD2bY1mdnSrbjDjcIVifmGpZTDjZZV{\WRiYomgUHBU MVuyOFMzPThzNh?=
fetal rat lung fibroblasts  M{izemtqdmG|ZTDBd5NigQ>? NXTzfnVoQDEQvF5CpC=> M4WwOFFp MmjobY5pcWKrdIOgR4F{eGG|ZT2zJIFkfGm4aYT5xsA> NW\WdnBnOjR|MUSxN|U>
PDL fibroblasts M2jaRmtqdmG|ZTDBd5NigQ>? M2e0fVgx|ryPwrC= NUexXYhFOWh? NIC1[HhqdmirYnn0d{BE[XOyYYPlMVMh[WO2aY\peJnDqA>? MXqyOFMyPDF|NR?=
MB49 M{S5WWFxd3C2b4Ppd{BCe3OjeR?= NY\TUIxNOjEQvF2= MUWxbC=> NGm2bphz\X[ncoPld{BEVS2rbnT1Z4VlKGOnbHyg[IVifGh? NFjjZ48zPDJ6MkSzNy=>
5637 NFPTcllCeG:ydH;zbZMhSXO|YYm= NH;Gc2gzOM7:TR?= NHLScZcycA>? NVvDXnBYemW4ZYLz[ZMhS01vaX7keYNm\CClZXzsJIRm[XSq MYCyOFI5OjR|Mx?=
A549  NXroSVczSXCxcITvd4l{KEG|c3H5 MYmxNFDPxE1? NFvqOXU1QGh? MXPzeZBxemW|c3XzJJRp\SCjcH;weI9{cXNiY3H1d4VlKGK7IIDpdIVzcW6nwrC= MWOyOFI4OjJyMR?=
MCC-2 NX\te3VsSXCxcITvd4l{KEG|c3H5 NGTWSHgzOCEQvF2= MX22bC=> NULUW2ljTE2VTx?= NGjtUodjdG:la4OgbY5lfWOnZDDifUB{fGG3cn;zdI9zcW6nIHHwc5B1d3OrczDj[YxtKGSnYYTo NVHCRmpLOjR{NkK2OVg>
ADF NUHI[2FzSXCxcITvd4l{KEG|c3H5 MYe0NO69VQ>? NI[1W3c3cA>? NYO3RlVvcW6qaXLpeJMh[XCxcITvd4l{KGmwZIXj[YQh[nliY3jlcY91cGW{YYD5JJBtfXNiWn7DcFI> M4DTWFI1OjJ6MkOy
 U373  NGroS2lCeG:ydH;zbZMhSXO|YYm= M4TkXlQx|ryP MofYOog> MWTpcohq[mm2czDhdI9xfG:|aYOgbY5lfWOnZDDifUBkcGWvb4To[ZJieHlicHz1d{BbdkOuMh?= NHXQVJYzPDJ{OEKzNi=>
RKO-HIPK2i NXHGfItDSXCxcITvd4l{KEG|c3H5 NH\0WGk1OM7:TR?= NHzpPIg3cA>? Mli2bY5pcWKrdIOgZZBweHSxc3nzJIlv\HWlZXSgZpkh[2inbX;0bIVz[XC7IIDseZMhYm6FbEK= Mn;SNlQzOjh{M{K=
HEC-1B MXXBdI9xfG:|aYOgRZN{[Xl? M3PkfFIx|ryP NFTaSmkycA>? NWPlTlFXemWmdXPld{BVWC2rbnT1Z4VlKGGyb4D0c5Nqe8LiY3HzdIF{\S1|IHHu[EBk[XOyYYPlMVk> M{TlWFI1OjF|M{W4
4T1 MmG0R4VtdCCYaXHibYxqfHliQYPzZZk> NIjNU2gzNjVvMUFOwG0> MmjnOIg> NWPKPWVYTE2VTx?= M2L5epJme2O3ZYOgeIhmKGO7dH;0c5hq[2m2eTDv[kA1XDFiY3XscJMhcW6mdXPl[EBjgSCVUFTUJIlvKGFiY3;uZ4VvfHKjdHnvckBl\XCnbnTlcpQhdWGwbnXy M3X2bFI1OjB4MU[x
OS  NXKzdnlNSXCxcITvd4l{KEG|c3H5 M2PYelIx|ryP MVK0bC=> MnzIbY5pcWKrdIOgeIhmKGOnbHyg[IVifGhiY3H1d4VlKGK7IGDEWC=> NUXadnlIOjR{MES5N|c>
RPE NFvDZW1CeG:ydH;zbZMhSXO|YYm= NHz0UJQyODEQvF2= NXPId4FLPDiq NYDJ[XlseGG{dHnhcIx6KGmwaHnibZR{KHSqZTDjZYxx[WmwLUGgZY5lKC1{IHHjeIl3[XSrb36gZZMhf2WubDDhd{B1cGViY3HzdIF{\SCjY4TpeoF1cW:w NF3CRpEzPDJyMkC1Ni=>
UD29a M2Ls[GFxd3C2b4Ppd{BCe3OjeR?= NXvaWGlWPTEQvF2= Mn[wNlRp NYfXPVNYcW6qaXLpeJMhfGinIHPlcIwh\GWjdHigZ4F2e2WmIHL5JG5WXDN? NWHTS29JOjRzOUC1O|Q>
SH-SY5Y  MnnZRZBweHSxc3nzJGF{e2G7 NE\xeo4yOM7:TR?= NGfiSZYzPGh? M4HNeYF1fGWwdXH0[ZMh[2G|cHHz[UBi[3SrdnH0bY9vKGGwZDDj[YxtKGSnYYToJIlv\HWlZXSgZpkhUE6HLULESy=> NYHJS2hMOjRzNEW0OlM>
HeLa  NYXmOIhGSXCxcITvd4l{KEG|c3H5 MoTZNVAwOjEQvF2= NUnwOWhZOjSq MlPubY5pcWKrdIOgeIhmKGGldHn2bZR6KG:oIITo[UBu[Wqxcnn0fUBw\iC2aHWgcYVu[mW{czDv[kB1cGViY3HzdIF{\S2oYX3pcJk> NYDXS2JsOjRzM{eyOlY>
SCCVII  NWeycnlpSXCxcITvd4l{KEG|c3H5 M4jqelI2|ryP MoDlNYg> NYS3TpFOcW6qaXLpeJMhfGinIHPlcIwhc2mubHnu[{Bi\nSncjDkZZNifGmwaXK= NGjlUGkzPDF{NkS2OC=>
RAW 264.7 M4rBRmFxd3C2b4Ppd{BCe3OjeR?= MoezNlDPxE1? M1LEXVE5cA>? NFnKXmNqdmO{ZXHz[ZMhVEN|LVnJM:6zNWGldHnuJJJifGmxIHPvcZBiemWmIITvJGVEXFZvTV;TJJRz\WG2bXXueEBwdmy7 NITBb4gzPDFzNkewOy=>
A549  M1rLeWFxd3C2b4Ppd{BCe3OjeR?= MUWyMlXPxE1? NVrCfZVZOjSq NIjqTIdl\WO{ZXHz[ZMhd3KrZH;ubY4ucW6mdXPl[EBifXSxcHjh[5kh[XNid3XscEBidmRiTH;zd{Bw\iEQlN-IcUBidHOxIH;jZ5VzemWmIHT1dolv\yCjdYTvdIhi\2mlIIDyc4Nme3N? NIrscYYzPDFyMkWyNi=>
UM-SCC-10A  M2TPNGFxd3C2b4Ppd{BCe3OjeR?= NXHE[JhkPTEEtV2= NWnUeWVXOmh? NETBemtz\WS3Y3XzJIFxd3C2b4Ppd{BqdmS3Y3XkJIJ6KGirZ3it[I9{\SCrc3;hcIFvfG:uYXP0c45m M3LKOVI1ODl6N{Wz
BGC-823 MXzBdI9xfG:|aYOgRZN{[Xl? NIn5bGcyOCEQvF2= MUWyOIg> MlfidoVlfWOnczD0[ZRz[W6mcnnu[U1qdmS3Y3XkJIFxd3C2b4Ppd:Kh MX[yOFA6QDVzMR?=
Nalm-6  MULBdI9xfG:|aYOgRZN{[Xl? NYm3VlZ2OjEQvF2= NUPqV|lGPGh? MkX6bY5pcWKrdIOgZ4F{eGG|ZT24JIFv\CClYYPwZZNmNTNiYXP0bZZifGmxbjDhcoQhWEGUUD2xJINt\WG4YXfl MXGyOFA{QTl4Nx?=
KHOS  MXHBdI9xfG:|aYOgRZN{[Xl? MV[0NO69VQ>? NGTkXmQzPGh? Ml3GZoxw[2u|IITo[UBqdmO{ZXHz[YQh[2ynYY\h[4Uhd2ZiY3HzdIF{\S1|IHHu[EBRSVKSIHnu[JVk\WRiYomgRmJOTDQEoB?= MXmyOFAzPTN4MR?=
G292 NWTpSYVtSXCxcITvd4l{KEG|c3H5 MWi0NO69VQ>? M3SwZVI1cA>? NWHSXm5b[myxY3vzJJRp\SCrbnPy[YF{\WRiY3zlZZZi\2Vib3[gZ4F{eGG|ZT2zJIFv\CCSQWLQJIlv\HWlZXSgZpkhSkKPRERCpC=> MX:yOFAzPTN4MR?=
MG-63 MXfBdI9xfG:|aYOgRZN{[Xl? MlnoOFDPxE1? NH:xN48zPGh? NV7ZS4dK[myxY3vzJJRp\SCrbnPy[YF{\WRiY3zlZZZi\2Vib3[gZ4F{eGG|ZT2zJIFv\CCSQWLQJIlv\HWlZXSgZpkhSkKPRERCpC=> NXfFRnNuOjRyMkWzOlE>
EBV-transformed B cells M4LkZ2Fxd3C2b4Ppd{BCe3OjeR?= M2PWO|Ix|ryP NXvn[WhNOmh? NYezc5R4TE2VTx?= NX7aZ|N3[myxY3vzJIFvfGlvQ1S4NEBidmRiYX70bU1ETDh4IHHueIljd2S7LXnu[JVk\WRiYYDvdJRwe2m| M4\KZ|I1ODB6NkK4
IM-9 B NXzINGNpSXCxcITvd4l{KEG|c3H5 MXGyNO69VQ>? NUTDN|VHOmh? NIrNXVlFVVOR MnrmZoxw[2u|IHHueIkuS0R6MDDhcoQh[W62aT3DSFg3KGGwdHnic4R6NWmwZIXj[YQh[XCxcITvd4l{ NU\hTHJjOjRyMEi2Nlg>
CNE1 MmX4RZBweHSxc3nzJGF{e2G7 MmTBNlDPxE1? M4Xhd|Q5cA>? NEXSToVjdG:la4OgUGsuSS2rbnT1Z4VlKGGyb4D0c5Nqew>? M{\y[VI{QTh3MEK5
CNE2 MlPSRZBweHSxc3nzJGF{e2G7 M4rwN|Ix|ryP M4DITFQ5cA>? NELxVlBjdG:la4OgUGsuSS2rbnT1Z4VlKGGyb4D0c5Nqew>? M1juPVI{QTh3MEK5
HL-60 MXLBdI9xfG:|aYOgRZN{[Xl? MnjvOVDDvU1? M4jBPFFp NYDUUVBbTE2VTx?= NHTJXHVqdmirYnn0d{BieG:ydH;zbZMhcW6mdXPl[EBjgSCEQUG0OS=> Mor1NlM6PDh5NUG=
L929 NIHFcGpCeG:ydH;zbZMhSXO|YYm= MX[xMlI26oDVNdMg{txOyqB? MkX4NlRp NVPvVmp2[XWpbXXueJMhXE6IzsGtbY5lfWOnZDDu[YNzd3C2b4Ppd{BidmRiYYX0c5Bp[We7 NIDOO|kzOzl2MUe2PS=>
Jurkat MnWzR4VtdCCYaXHibYxqfHliQYPzZZk> MWGy{txO M4\xVVRp Ml7NdoV3\XK|ZYOg[5Jwf3SqIHnubIljcXSrb36gZY5lKM7{LXPheIVvcW5iZHXjdoVie2ViYomgTHMuSVOD MUKyN|g6PjB4MR?=
RAW264.7  MnWwRZBweHSxc3nzJGF{e2G7 NWnTcFhUOTBizszN NXi0c|d3OjSq MYnk[YNz\WG|ZYOgeIhmKGGyb4D0c5NqeyCrbnT1Z4VlKGK7IFfB M2\qSVI{QDJyMkCz
A431  MVjLbY5ie2ViQYPzZZk> M4HpTlQx|ryP NIDucmUzcA>? MlfjZoxw[2u|IH\pd4V1cW5vaX7keYNm\CClbHXheoFo\SCxZjDjZZNx[XOnczDhcoQhWEGUUB?= MYGyN|gxODB3OB?=
Jurkat MXrD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NGG5OpUzPS1zMEFOwG0> MXG2bC=> MlzPbY5pcWKrdIOgfk1HSS2FTVutbY5lfWOnZDDj[YxtKGSnYYTo NHrOdJAzOzl|M{WzNi=>
COS-7  MnrWSpVv[3Srb36gRZN{[Xl? MlrPOVDDvU1? Ml\yNlRp NGDvclBi\m[nY4TzJJRp\SCycn;j[ZN{cW6pIH;mJGFVVjG|IIfpeIgheG:ueWGgeJJi[3S| MWGyN|k{OzJyOB?=
CAL27 M3W2S2Fxd3C2b4Ppd{BCe3OjeR?= M{LE[|ExKM7:TR?= MV[ybC=> M3e2PJN2eHC{ZYPz[ZMhS3W{LV7Qd{1z\WS3Y3XkJJZq[WKrbHn0fUBjgSC3cDD0c{A6OCV? NXfPWo41OjN7MUezPVY>
THP-1  M3nERmFxd3C2b4Ppd{BCe3OjeR?= MkCwNVAuPTEQvF2= MoDKNog> MlH2bY5pcWKrdIOgZZBweHSxc3nzJIlv\HWlZXSgZpkhfHKrcITvcIll\Q>? NVzTc3VrOjN7MECyPVk>
K562 M{f0fmFxd3C2b4Ppd{BCe3OjeR?= MWWyNO69VQ>? NIjhWYU1QGh? NF7ZR4NqdmirYnn0d{BieG:ydH;zbZMhcW6mdXPl[EBjgSB2LV3V NIPSb|kzOzh5NkiyOi=>
HL-60 Ml[wRZBweHSxc3nzJGF{e2G7 NXT6[3g2OTByzszN MoqwNlRp NVnWbo9zcW6qaXLpeJMh[XCxcITvd4l{KGmwZIXj[YQh[nliYXLp[ZRidmViZHn0[ZJx\W6nc9Mg NGjvOXMzOzh4NUe3PC=>
HeLa  NVHEXlRJSXCxcITvd4l{KEG|c3H5 MlTyNlDPxE1? NH30NVYzcA>? MVTpcohq[mm2czDEUW1RKGmwZIXj[YQh[XCxcITvd4l{ M1zhWlI{QDZ|OU[2
U251 MonYRZBweHSxc3nzJGF{e2G7 M4L5V|Ix|ryP Mm\vNlRp M{G3XolvcGmkaYTzJINie3SrY3nuJIlv\HWlZXSgS|IwVSCyaHHz[UBienKnc4SgZY5lKGGyb4D0c5Nqew>? NYP5PFFDOjN6MU[4NVY>
HL-60 M2m5NGFxd3C2b4Ppd{BCe3OjeR?= Ml\IOVDDvU1? MYC0bC=> M4DKVYJtd2OtczD0bIUh[2ynYY\h[4Uhd2ZiY3HzdIF{\S1|LDCtPUwh[W6mIGDBVnAhcW6mdXPl[EBjgSB4cx?= MkTBNlM5ODR5ME[=
Ec-109 MW\BdI9xfG:|aYOgRZN{[Xl? MU[xNEDPxE1? M4DMS|Q5cA>? NH62e5Zz\XC{ZYPz[ZMhWEVvbXXkbYF1\WRiRXOtNVA6KGOnbHygZZBweHSxc3nz MYqyN|c5OjZ2MR?=
RKO NYLOfGJMS2WubDDWbYFjcWyrdImgRZN{[Xl? MojvNVAh|ryP M4DmclI1cA>? NXHWN2NicW6qaXLpeJMhfGinIHTlZ5Jm[XOnIH;mJINmdGxidnnhZoltcXS7IHPheZNm\CCkeTDERWI> M3jCPVI{PzV6ME[0
T98G NFHoUIhE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MkDtNU0yODEQvF2= NV:1b2NQOjSq NIG3e|JqdXC{b4\ld{Bk\WyuII\pZYJqdGm2eTDjc5Rz\WG2bXXueEB4cXSqIGTT NIK3bnczOzd4OUK3OS=>
Jurkat NV;Fc|VMS2WubDDWbYFjcWyrdImgRZN{[Xl? M3nJbFExOC1{MEFOwG0> NYPwZYtjOjSq M3Hke4lvcGmkaYTzJGhiSTRiaX7keYNmeyCjcH;weI9{cXNiZHXw[Y5l\W62IH;mJINwdmOnboTyZZRqd28EoB?= MUWyN|c{OjR6MR?=
Molt-3  M3TucGFxd3C2b4Ppd{BCe3OjeR?= NF7iNI02OM7:TR?= MUGybC=> M3W1VpJm\HWlZYOgcYVt[XSxbnnuMYlv\HWlZXSgZZBweHSxc3nz MVOyN|czPTBzMx?=
hMSC12 MVjBdI9xfG:|aYOgRZN{[Xl? M4fncVExOM7:TR?= M{fHeFRl Mn3ybY5pcWKrdIOgc5N1\W:pZX7pZ{BkfWy2dYLlMYlv\HWlZXSgZ4VtdCCmZXH0bEBidmRiY3HsZ4lncWOjdHnvci=> MnPQNlM3PTd6MkK=
HM7  MV3BdI9xfG:|aYOgRZN{[Xl? NWnoWGxJOjEQvF5CpC=> NYG1[FA3OWh? NWTR[Wpj[myxY3vzJIFxcWO3bHHy[Y4hSSCjY3X0ZZRmNWmwZIXj[YQh[2G|cHHz[U0{KGGldHn2ZZRqd25iYX7kJHBCWlBiY3zlZZZi\2V? NVXwO3hzOjN3OEO0NVI>
Hep-2  MXPBdI9xfG:|aYOgRZN{[Xl? NHf0Um0zOM7:TdMg MUiyOIg> NWG0fZNRTE2VTx?= MWnhcIxmfmmjdHXzJJRp\SCmZXPy[YF{\SCxZjDj[YxtKH[rYXLpcIl1gSCrbnT1Z4VlKGK7IIPpcIljcW6rbh?= NU[yZVVCOjN3OECwN|I>
HSCs NXnUUXJ3SXCxcITvd4l{KEG|c3H5 NIKyUm42OM7:TR?= MknMNlRp NXy3W5ZtTE2VTx?= MVzpcohq[mm2czDubYxwfGmwaXKtbY5lfWOnZDDEUmEh\GGvYXflJIlv\GmlYYTl[EBjgSCSQWLQJINt\WG4YXfl M3zHfFI{PDl7OEe0
HL-60  MXfDfZRwfG:6aXPpeJkhSXO|YYm= NX3idFU2OjEQvF5CpC=> M4TIRlI1cA>? MnjzdoVlfWOnczD0bIUh[3m2b4TvfIlkKGWoZnXjeEBw\iCHcom1 NGewRZIzOzR7NES4NC=>
HA M2ftXmFxd3C2b4Ppd{BCe3OjeR?= NFTnd5o2OM7:TR?= NIXPcpkzPGh? M3zXVpN2eHC{ZYPz[ZMhfGinIHPs[YF3[WenIH;mJHBCWlBiYX7kJINie3Cjc3WtN{whNTduIHHu[EAuQSCrbnT1Z4VlKGK7IHLvdpRmgm:vaXKvV2FJSQ>? NVHkeYVbOjN2N{W5OVY>
C666-1 MVHBdI9xfG:|aYOgRZN{[Xl? MYC1NO69VQ>? M3\KUVI1cA>? NHG2Tmx{fXCycnXzd4V{KHSqZTDjcIVifmGpZTDv[kBRSVKSIHHu[EBk[XOyYYPlMVMtKC15LDDhcoQhNTliaX7keYNm\CCkeTDic5J1\XqxbXniM3NCUEF? MV2yN|Q4PTl3Nh?=
Hepa1-6 MXrBdI9xfG:|aYOgRZN{[Xl? MX61NO69VQ>? NVToNnlnOmh? MYjpcohq[mm2czDjeZJkfW2rbjDhcoQhemW|dnXyZZRzd2xvaX7keYNm\CCjcH;weI9{cXN? MVWyN|Q1Pjd3Mx?=
PLC/PRF/5c M{DLdGFxd3C2b4Ppd{BCe3OjeR?= MWS1NO69VQ>? Mmq3NYg> M1HNfJBz\X[nboTzJIFxd3C2b4Ppd{B1emmpZ3Xy[YQh[nliQ1nO M37UXFI{PDN6OEK0
HCT116 Mn\FRZBweHSxc3nzJGF{e2G7 M3K4bVExOM7:TR?= MXmxMlVp MoHlbY5pcWKrdIOgU5MucW6mdXPl[EBk\WyuIHTlZZRp MXyyN|c1PDN3Mx?=
HCEC MX3GeY5kfGmxbjDBd5NigQ>? NYjzNJBmPTEQvF2= NWHh[3U5PzKq NF\4PY9FVVOR MlvkdoV{fG:{ZYOgc4YhfGinIH7vdo1idCCKQ1XDJJBp\W6xdInw[S=> NYXxcFNTOjN5NEKwNVE>
Primary rat cerebral cortical neurons M3O4U2Fxd3C2b4Ppd{BCe3OjeR?= NF3HdJIyODEQvF2= NVnBbXJDOWh? MmPidJJmfmWwdIOgR4QucW6mdXPl[EBieG:ydH;zbZMh[W6mIHPlcIwh\GWjdHi= MlTRNlM4PDF|MUe=
MDA-MB-231  M{fmVmFxd3C2b4Ppd{BCe3OjeR?= NVqzcJVYOjYQvF2= MlfNNlRp M4PSboFjem:pYYTld{BkgXSxdH;4bYNqfHliYX7kJINt\WG4YXflJI9nKGOjc4Dhd4UuOyCjbnSgVGFTWCCrbnT1Z4VlKGK7IGLnNy=> NF\ESW4zPTN|N{W0OC=>
NLRP3-Tet-on-MC/9  Mmn0RZBweHSxc3nzJGF{e2G7 NU\Qe2JoOTBvNEFOwG0> MWKxNog> MlHsZZR1\W63YYTld{B1cGViY3XscEBl\WG2aDDjZZV{\WRiYomgR2FRWy2jc4PvZ4lifGWmIF7MVnA{KG23dHHueJMhcW5idHjlJHRmfC2xbjDzfZN1\W1? MYSyN|cxOzN6OR?=
KNS42  MUnBdI9xfG:|aYOgRZN{[Xl? MWm1NO69VQ>? M4\1TlFp MWfy[YR2[2W|IHPlcIwh\GWjdHigZY5lKGOxbYDs[ZRmdHliYXLvcIl{cGWmIHPhd5Bie2ViMz:3JIFkfGm4aYT5JIlvKHKnc4DvcpNmKHSxIFHCWE0zPjNxMlTHM41mfG[xcn3pckBkd22kaX7heIlwdg>? NVLTO5V1OjN4OUGxOFU>
MCF-7  MYfBdI9xfG:|aYOgRZN{[Xl? M1rybFIx|ryPwrC= M1:1Z|czcA>? MkflbY5pcWKrdIOg[ZF2d2xvIHHu[EA1NU:KVD3t[YRq[XSnZDDhdI9xfG:|aYO= MYSyN|Y4PTZ2Mx?=
hCMEC/D3  NHLkPVhCeG:ydH;zbZMhSXO|YYm= M4rIXlI2|ryP NFzDT2I4Omh? MVLy[YR2[2W|IFz0fGEhcW6mdXPl[EBieG:ydH;zbZM> NHLtTXQzOzZ4NUG5PC=>
Jurkat MUHBdI9xfG:|aYOgRZN{[Xl? MUexNk42NTVyzszN NWPKeYlXOWh? Mn7j[I9{\SCmZYDlcoRmdnSueTDzeZBxemW|c3XzJHNRUC2rbnT1Z4VlKFCjcj20JINt\WG4YXflMEBRSVKSIHPs[YF3[WenLDDEUmEh\nKjZ33lcpRifGmxbjygZY5lKGyxc4Ogc4YhfmmjYnnsbZR6 NYn3U5Y2OjN2NEK5O|Y>
CNE-1 MoLRRZBweHSxc3nzJGF{e2G7 MkfyNlDPxE4EoB?= NYHSZ2VKOjSq M{TVXIlvcGmkaYTzJHJCTDByMT3pcoR2[2WmIHPlcIwh\GWjdHi= NVHEPGVzOjN2Mk[4OVA>
HONE-1 MnXuRZBweHSxc3nzJGF{e2G7 MoDKNlDPxE4EoB?= MVWyOIg> M1LnW4lvcGmkaYTzJHJCTDByMT3pcoR2[2WmIHPlcIwh\GWjdHi= MVeyN|QzPjh3MB?=
astrocytes cell NHqydHlCeG:ydH;zbZMhSXO|YYm= NF21PHg1OM7:TR?= NF;3dVc3cA>? MUny[YR2[2W|IHXhdox6KGGyb4D0c5NqeyCrbnT1Z4VlKGK7IIP0ZZVzd3Oyb4LpcoU> NVfTb4s4OjN2MUG3O|g>
U-937 M1Tj[WFxd3C2b4Ppd{BCe3OjeR?= NEmzOIsyOM7:TR?= M2TCXlMxdWmw MkfwdJJmfmWwdIOgWG5HNWmwZIXj[YQhdmWlcn;weI9{cXN? NInneWwzOzRzMEe0PC=>
MDA-MB-231 NFXReI9CeG:ydH;zbZMhSXO|YYm= NV3XbXdjOTByzszN MmT6NYg> M3raTIlvcGmkaYTzJJNmdnOrdHn6ZZRqd25idH:gWHJCUUxidYDvckBOXESKIHTve44uemWpdXzheIlwdg>? MU[yN|QxQDR{OR?=
HeLa  NIWzW2hCeG:ydH;zbZMhSXO|YYm= M13helExOM7:TR?= NILleZUzcA>? NGnYWFZjdG:la4OgTnJUNTF3IFnu[JVk\XNiQYDvdJRwfGmlIFPlcIwhTGWjdHi= NWXHZmk{OjN|NESwOFU>
Ec109 MYTBdI9xfG:|aYOgRZN{[Xl? MVOxNO69VQ>? M2LZ[lZp M{LQT4Jtd2OtczDhdI9xfG:2aXOgZ49u[mmwYYTpc44hd2ZiVHH0MXNu[WOQNzDhcoQhemGmaXH0bY9v NYPNSXBYOjN|M{i1Olg>
H460  M4fYNWFxd3C2b4Ppd{BCe3OjeR?= NXP5V4J5OTEQvF2= MmHhOog> NXTsSGo6[myxY3vzJIFxd3C2b4TpZ{Bkd22kaX7heIlwdiCxZjDUZZQuW22jY163JIFv\CC{YXTpZZRqd25? MmDNNlM{Ozh3Nki=
HeLa  NX\ib2hVSXCxcITvd4l{KEG|c3H5 NE\MWYE2OM7:TR?= NG[3ZZYyNjWq M2fUXoFjem:pYYTld:KhS2iuYX35[IliNWmwZIXj[YQh[XCxcITvd4l{ NXHseGdEOjN|MEO4NFQ>
SK-HEP1 MXrBdI9xfG:|aYOgRZN{[Xl? NIftWHcyODEQvF2= MkjlNYg> MoHtbY5pcWKrdIOgR5JVOSCjY4TpeoF1\WRiY3HzdIF{\S1|LDCtO{whNThuID25MEBidmRicH;sfUhCTFBvcnnic5NmMSCyb3z5cYVz[XOn NG\0PIkzOzNyMk[1NC=>
QGY7701 M4S5bGFxd3C2b4Ppd{BCe3OjeR?= MnvDNlXPxE1? MkWzNU42cA>? M4fOVIlvcGmkaYTzJIFk[3WvdXzheIlwdiCxZjDzeYIuTzFicHjhd4UhcW6mdXPl[EBjgSCGT2igL{ByfWW{Y3X0bY4> M4rmclI{OjRyME[x
HepG2 NYS2NlNsSXCxcITvd4l{KEG|c3H5 NFHUR3MzOM7:TR?= MoPxN|BucW5? MV;pcohq[mm2czD0bIUh\W6qYX7j[YQh[2WubDDk[YF1cCCkeTDjc41jcW6nZDD0doVifG2nboSgc4Yh[XCrZ3XubY4h[W6mIGTSRWlN MlzNNlMzOjR{M{m=
U87  NInUNZpCeG:ydH;zbZMhSXO|YYm= M37ZZlI2|ryP MlzwNog> NUPxV2VM\GWlcnXhd4V{KGm|b3zpdZVqemm2aXflcolvKCiLU1ypMYlv\HWlZXSgZZBweHSxdHnjJINmdGxiZHXheIgtKGK3dDDuc5QhdmWlcn;0bYMh[2WubDDk[YF1cA>? M3\FeFI{OjJ7NkK2
HSC-2 MonFRZBweHSxc3nzJGF{e2G7 NV3UPVV5OjVxNUFOwG0> M{e5d|Fp MnzjbY5pcWKrdIOgV24uOzhvaX7keYNm\CCleYTveI95cWOrdIm= NVnwOXQyOjNzNUWyOFg>
HSC-4 M2\wUWFxd3C2b4Ppd{BCe3OjeR?= NEnaV|EzPS93MN88US=> MljaNYg> MmjEbY5pcWKrdIOgV24uOzhvaX7keYNm\CCleYTveI95cWOrdIm= MYeyN|E2PTJ2OB?=
CL-1 NHvDbHBCeG:ydH;zbZMhSXO|YYm= NVfvbGNROjEQvF2= M{HSOlFp MVjicI9kc3NiT2C0OFkhcW6mdXPl[EBk\WyuIHTlZZRp MVSyN|E{OTd6Mh?=
MEL NFrQXW1CeG:ydH;zbZMhSXO|YYm= M3jIcFIx|ryP NIriSFAzPGh? Mmf3SG1UVw>? M2f5PIlueGGrcnXzJHAzYDdvaX7keYNm\CCPRVygZ4VtdCCjcH;weI9{cXN? NGLpbnIzOzBzNEi4Oy=>
Bel-7402  M3fFTWNie3Cjc3WgRYN1cX[jdHnvckBCe3OjeR?= MlTxOVDPxE1? NUmydo1{Omh? NHXBSpdqdmirYnn0d{BRS0VvaX7keYNm\CCjbn;pb4l{ M3KwTlI{ODB6N{Sy
Eca-109 NYLZNo1SSXCxcITvd4l{KEG|c3H5 M{PIVlI2|ryP MYGzNI1qdg>? M1zvPIlvcGmkaYTzJGJLNUJzMT3pcoR2[2WmIHPlcIwh\GWjdHi= M1TaVlI{ODd4OU[3
MEL NVThNWFoSXCxcITvd4l{KEG|c3H5 MnzONlDPxE1? NV7NcGQ6OWh? M3vlSmROW09? M33lcolueGGrcnXzJHAzYDdvaX7keYNm\CCPRVygZ4VtdCCjcH;weI9{cXN? NX7JXmpDOjNyMUS4PFc>
Bel-7402  MnHyRZBweHSxc3nzJGF{e2G7 MmTDOVDPxE1? NIrMdpgzcA>? NVLvS3RIcW6qaXLpeJMhWEOHLXnu[JVk\WRiYX7vbYtqew>? NEn0[IszOzByOEe0Ni=>
L929 NHm2dG5HfW6ldHnvckBCe3OjeR?= NIPNUXQzNjYQvF2= NGnHNJMycA>? NHf0cWRqdmO{ZXHz[ZMhWkmSMTDlfJBz\XO|aX;uJIFv\CCneHHj[ZJj[XSnZDDUUmbPuS2rbnT1Z4VlKG2rdH;jbI9v\HKrYXyg[Jl{\nWwY4Tpc44h[W6mIGLPV{Bxem:mdXP0bY9v MmPZNlMxODB3MUi=
RCC  NFTp[mNE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NFLINFMyODEQvF2= M3S0eVI1cA>? MVry[YNwfmW{ZYOgeIhmKH[rYXLpcIl1gSCxZjDj[YxteyCneIDvd4VlKHSxIEG1[E1RT0p{ MnroNlI6QTF2OUS=
NB2a/d1 MnXQRZBweHSxc3nzJGF{e2G7 MorpNVAx|ryP NHL6d|g4Omh? NVnSZo5P[XS2ZX71ZZRmeyC|dHH1do9{eG:{aX7lMYlv\HWlZXSgZ4F{eGG|ZTDhZ5Rqfmm2eTygVGFTWCxiYX7kJJRifSClbHXheoFo\Q>? MVuyNlk5QDV2MR?=
T cell MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHPIZ3AzPS1zMEFOwG0> MXGyOIg> MYjkc5NmNWSncHXu[IVvfGy7IHnubIljcXSnZDDUJINmdGxicILvcIln\XKjdHnvckBu\WSrYYTl[EB1cHKxdXfoJJRp\SClbz3zeIlufWyjdHnvckB4cXSqIHHueIkuS0R|IHHu[EBidnSrLVPENlg> M3fwc|IzQTh{NUO4
K562 NV;4OYlQSXCxcITvd4l{KEG|c3H5 M4nBZ|ExOM7:TR?= MkfaNYg> MlrVZoxw[2u|IFHico9j[X[rc3P1ceKhTi2rbnT1Z4VlKGGyb4D0c5Nqew>? M1jPSFIzQTd{M{ey
Jurkat  M3fleWFxd3C2b4Ppd{BCe3OjeR?= M4D4d|Qx|ryP MmPGNYg> MmfVZYJwdGm|aHXzJGZie0xvaX7keYNm\CClYYPwZZNmKGGldHn2ZZRqd25iYX7kJINmdGxiZHXheIg> MofXNlI6PDJ5M{i=
BGC-823 MWPBdI9xfG:|aYOgRZN{[Xl? M4LBcFExOM7:TR?= MmKwNYg> MUXwZZJ1cWGubImgdoV{[3WnczDj[YxteyCjZ3HpcpN1KGSjbXHn[UBw\iCmYXnkfoVqdg>? M4fxPFIzQTJ4NUS1
Hep3B MWDBdI9xfG:|aYOgRZN{[Xl? MmnPOVDPxE1? MUGxbC=> NUnVcFhF[myxY3vzJIFxd3C2b4Ppd{BqdmS3Y3XkJIJ6KEiHR1Pz M4XTbVIzQTJ|MUW0
LLC-PK1 MV\BdI9xfG:|aYOgRZN{[Xl? NVXzUWhZOjEQvF2= NF;5cGIycA>? MlT5dJJmfmWwdIOgZ4l{eGyjdHnuMYlv\HWlZXSg[IVoemGmYYTpc44hd2ZiQYTnOUwh[mWlbHnuMVEtKGGwZDDBeIcyOiCycn;0[Ylvew>? MoXYNlI5QTZyM{e=
A549 MXHBdI9xfG:|aYOgRZN{[Xl? NFj6XHQ2OM7:TR?= NXLSSWV6OWh? Mnm3Zoxw[2u|IITo[UBDSUlvaX7keYNm\CCjcH;weI9{cXQEoB?= MW[yNlg5PzJzNR?=
SGC-7901  NV;vUnhWSXCxcITvd4l{KEG|c3H5 MY[xNO69VQ>? NH;rSpgzPGh? NX62RZJQcW6qaXLpeJMh|rJuzsKt[Ilu\XSqeXzhZ5J6dHOqaXvvcolvNWmwZIXj[YQh[XCxcITvd4l{yqB? MoTFNlI5PDh3OUe=
DM6 MV7BdI9xfG:|aYOgRZN{[Xl? NEDK[WQyODEQvF2= M{TaeVczcA>? MYricI9kc3NiYn;0bEBGOkZvMTDhcoQhTTKIdIKtcYVlcWG2ZXSgZ5l1d3SxeHnjbZR6 MnLYNlI5OjV|Mki=
MCF-7, MDA-MB-468, Caco-2 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXK1NO69VQ>? M3rPNlQ5cA>? NH7YSmVqdmirYnn0d{B1cGViY3XscEBoem:5dHigbY5pcWKrdHnvckBqdmS3Y3XkJIJ6KHOjcH;ubY4> NEjrWGQzOjhyMEm2PC=>
A2750  NUHZVlZySXCxcITvd4l{KEG|c3H5 MnG5NlDPxE1? MnXTNog> MnrBSG1UVw>? NFLCVINjdG:la4OgZ4F{eGG|ZTDjcIVifmGpZTDkeZJqdmdiaHXs[Y5idGmwIITy[YF1dWWwdDDhcoQhemWmdXPld{BifXSxcHjh[4lkKGOnbHyg[IVifGh? MoPrNlI4QDR|NkO=
U87  NEmzVGNCeG:ydH;zbZMhSXO|YYm= NFvWWGczOM7:TR?= MWOyOIg> Mn3MdoVlfWOnczD0bIUh[XCxcITvd4l{KHKjdHWgbY5lfWOnZDDifUBRVEGE Moe2NlI4Pzh5OEC=
HT1080 NH22dYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFrqdnc2OM7:TR?= MVe3[C=> NUXlepdlcW6qaXLpeJMhfGinIHPlcIwh\3Kxd4ToJIlvcGmkaYTpc44h[2G3c3XkJIJ6KGOxbXLpcoVlKHS{ZXH0cYVvfCCxZjDER2Eh[W6mIF;NVC=> NX3acWFoOjJ5NEC5PFQ>
A549  NFezVIhCeG:ydH;zbZMhSXO|YYm= M3nzS|Ux|ryP M3Hlc|Jp MkDYdIFzfGmjbHz5JIRm[3KnYYPld{B{d2SrdX2gd4Vt\W6rdHWtbY5lfWOnZDDhdI9xfG:|aYO= NXLIXI94OjJ5MkG4NFQ>
Primary OPC MoL6RZBweHSxc3nzJGF{e2G7 NUPiXYdnOc7:TR?= NXjRW4lGPmhxMkTo M1jCNZJm\HWlZYOgeIhmKHCncnPlcpRi\2Vib3[gZ4VtdHNiaX6g[YFzdHlvIHHu[EBt[XSnLXHwc5B1d3Orcz;u[YNzd3Orcx?= NFnKXVUzOjdyN{O4OS=>
PMNs MonDRZBweHSxc3nzJGF{e2G7 MV60NO69VQ>? M2r6dVZp M1fDUmROW09? M135ZZJmfmW{c3XkJJRp\SCjbX;1cpQhd2ZiY3zlZZZm\CClYYPwZZNmNTNidH:gcoVieiC4ZXjpZ4xmKGyndnXsdy=> NYX6PXVPOjJ4OUK1O|c>
A549  M3PwW2Fxd3C2b4Ppd{BCe3OjeR?= MXG1NO69VQ>? MXqxbC=> MoPidJJmfmWwdIOgZZBweHSxc3nzJIlv\HWlZXSgZpkhSmGxaIXvd4ll\SCL MWmyNlY5PzZ|NR?=
AGS M1HFW2Fxd3C2b4Ppd{BCe3OjeR?= MXGyNO69VQ>? M3vjSlEzcA>? NFnzZYRqdmirYnn0d{B1cGViYXP0bZZifGmxbjDv[kBxem9vY3HzdIF{\S1|IHnuJJJme3CxboPlJJRwKHSqZTDFeG9C[yCocnHjeIlwdg>? MWmyNlY5PzN7OB?=
shC9  M1r5dWFxd3C2b4Ppd{BCe3OjeR?= Mke0NVDPxE1? NGP3UWUyPmh? NGPDfINjdHWwdIOgV2hJKGW6cILld5Nqd25iaX6gd4hEQSClZXzsd{BmgHCxc3XkJJRwKGWrdHjldkBRSSCxcjDMVGM> MnmzNlI3PDFyOUS=
primary MEFs MlSzSpVv[3Srb36gRZN{[Xl? NXm5W5hDOTKq NILuSXHDqGmwY4LlZZNmeyCndH;wc5Nq\GVvaX7keYNm\CCvaYTvZ4hwdmS{aXHsJI1mdWK{YX7lJIRmeG:uYYLpfoF1cW:w M2facFIzPjF|N{[3
3T9 MEFs MmC1SpVv[3Srb36gRZN{[Xl? NGnld4kyPmh? M4jWW4lv[3KnYYPld{BkgXSxY3jyc41mKGNicnXs[YF{\SCjZoTldkBmfG:yb4Pp[IUufHKnYYTt[Y51 NITnfpgzOjZzM{e2Oy=>
3T9 MEFs MlLBSpVv[3Srb36gRZN{[Xl? NUPxRphbOTiq NXfF[YNvfXC{ZXf1cIF1\XNiaX7peIlifG:{IHPhd5Bie2VvOTDieZQh\G:5boLl[5Vt[XSnczDl[oZm[3SxcjDjZZNx[XOnczDh[pRmeiCndH;wc5Nq\GVidILlZZRu\W62 M2HnTFIzPjF|N{[3
MDA-MB-231  NYruVXVMSXCxcITvd4l{KEG|c3H5 M3XHTVIx|ryP NVfETXFDPGR? MYny[YR2[2W|IITo[UBk\WyuIHHwc5B1d3OrczDpcoR2[2WmIHL5JI1mfG[xcn3pckB1emWjdH3lcpQhf2G|IIPp[45q\mmlYX70cJk> NF3tUFEzOjV7M{S0NS=>
C6  NGP1NmpCeG:ydH;zbZMhSXO|YYm= MWSxNO69VQ>? Ml7NNlRp NFr5S4hjdG:la4OgeIhmKHO3cIDy[ZN{cX[nIHXm[oVkfCCxZjD0bIUheGWydHnk[UBwdiC4aXHibYxqfHl? MXSyNlU5QDl6MB?=
HL-60  MnfYRZBweHSxc3nzJGF{e2G7 MX[xNFDPxE1? NI\j[XgzPGh? NUDNW|dPcW6qaXLpeJMhfGinIHPlcIwh[XCxcITvd4l{KHOnbHXjeIVlKChtKT3t[Y51cHmuIN8yMUgy6obUNjmt[IlodHWlb4D5doFvd3OrZHZCpFU> M4T5d|IzPTR4Nk[5
HL-60 NF6zPWVCeG:ydH;zbZMhSXO|YYm= NYjxNJNMOTBvOEFOwG0> NFTqRYE1cA>? NEPaSnZqdmirYnn0d{BVT0iTLXnu[JVk\WRiY3XscEBieG:ydH;zbZPDqA>? MUWyNlUzOzJ{OR?=
BCC Mkn1RZBweHSxc3nzJGF{e2G7 MUi1NO69VQ>? MkP4NYg> M{D5TIlvcGmkaYTzJGRCXFNvbXXkbYF1\WRiZ4Lve5RpKGmwaHnibZRqd25? NYPJZ4I{OjJ3MUm0N|Y>
RAW 264.7 MlvHRZBweHSxc3nzJGF{e2G7 MX21NE8yODEQvF2= NH\zOogycA>? MXnjc45k\W62cnH0bY9vNWSncHXu[IVvfCCrbnjpZol1eyCGT16tbY5lfWOnZDDyVm5CKGOuZXH2ZYdm MVGyNlQ6OTR{Nh?=
K562 NILjdFNCeG:ydH;zbZMhSXO|YYm= MXGyOe69VQ>? MVGybC=> NF\YfZRxemW4ZX70d{BieG:ydH;zbZMhcW6mdXPl[EBjgSClbz30doVifG2nboSge4l1cCCjbYXy[Y5{cW5iRzDhcoQhXFKDSVy= M2LJWFIzPDh|N{e3
SGC-7901 NEG0fJFCeG:ydH;zbZMhSXO|YYm= M4GyOVIxKM7:TdMg M1H0PVJp MWTheJRmdnWjdHXzJGgzVzMEoH;yJHRPTiEQsT3pcoR2[2WmIHPlcIwh[XCxcITvd4l{KGG|IIflcIwh[XNiY3HzdIF{\S1|IHHjeIl3cXS7wrC= MYiyNlQ4OTV6OR?=
PC3 MnjnRZBweHSxc3nzJGF{e2G7 NInHU2wyOM7:TR?= NHPwZpg1cA>? NXjIO5hL[2:3boTldpMh\myjdn;jc5hq\C2rbnT1Z4VlKGOjc4Dhd4UuemWuYYTl[EBieG:ydH;zbZM> NEfsd2kzOjR5MUm3OC=>
SMMC-7721 NXXObVFHSXCxcITvd4l{KEG|c3H5 NIjsTm02OM7:TR?= M3zMfFQ5cA>? NUDTdHQ2[XS2ZX71ZZRmeyCxVGKtbY5lfWOnZDDhdI9xfG:|aYO= NULUNXdQOjJ2NkW4N|M>
HeLa  MVnBdI9xfG:|aYOgRZN{[Xl? MVS1NOKh|ryP MYq0M|hp NIjpXGhqdmirYnn0d{BUXFNvaX7keYNm\CCuYYTlMZBp[XOnIHHwc5B1d3SrYzDleoVvfHN? Mnv3NlI1PjB3MES=
HeLa  NV\oeoZSSXCxcITvd4l{KEG|c3H5 M4PXWVUxyqEQvF2= MnP4NYg> MV\zeZBxemW|c3XzJJRp\SCIUlHQMYlv\HWlZXSgZYNkfW23bHH0bY9vKG:oIHHucoV5cW5iVjDwc5NqfGm4ZTDj[Yxtew>? NXPyVZhqOjJ2NEm0OFA>
T47D  MWjBdI9xfG:|aYOgRZN{[Xl? M4\JNVExOM7:TR?= MmG1NYg> NGjYVVRjdG:la4OgeIhmKGenbnXyZZRqd25ib3[gSU1k[WRxQ2TGNkBjgSCVVGO= NETJbXIzOjRyMUG2PC=>
HeLa  MlzORZBweHSxc3nzJGF{e2G7 M37XZVMx|ryP NEPNVpc1cA>? M1jTVeKhcW6lcnXhd4V{KHSqZTDn[Y5memGuIHPlcIwhfmmjYnnsbZR6KDR6IHigZYZ1\XJicHjveI9lgW6jbXnjJJRz\WG2bXXueOKh NYrYT|hLOjJ|OUSyOFg>
HCC MnjURZBweHSxc3nzJGF{e2G7 MlHhNlAh|ryPwrC= NWL3UVVQOmh? MV7heJRmdnWjdHXzJJRp\SCGSFGgbY5lfWOnZDDhZ5RqfmG2aX;uJI9nKFCDUmC= MWKyNlM1Ojd|Mh?=
mESCs NVu4Wo1VSXCxcITvd4l{KEG|c3H5 MXqyMlXPxE1? M3ewZVJp MXXpcohq[mm2czD0bIUhVmGILX3l[IlifGWmIHPhd5Bie2ViYXP0bZZifGmxbh?= NGnkd4ozOjJ6NUK3OC=>
EMT-6  NI\DfoREgXSxdH;4bYNqfHliQYPzZZk> M1jzOlExOM7:TR?= MoO2NYg> Mn\GdIFzfGmjbHz5JIJtd2OtZXSgZ4VtdCCmZXH0bEBqdmS3Y3XkJIJ6KHOrcnHt[ZNqdmV? M{XIW|IzOjVzOUKx
MCF7 NWLVOFRYSXCxcITvd4l{KEG|c3H5 MW[1NOKh|ryP M{LHN|Fp MYjpcohq[mm2czDQRUBi[3SrdnH0[YQh[2G|cHHz[U0{NCBvOTygZY5lKHCxbImoRWRRNXKrYn;z[UkheG:ueX3ldoF{\Q>? MVuyNlIzOzN2NR?=
K562 MYHBdI9xfG:|aYOgRZN{[Xl? M4C3clIxKM7:TdMg NF3NXVA1QGh? NF2wPG1FVVOR MnvmZoxw[2u|IHzhdIF1cW6rYj3pcoR2[2WmIHnubIljcXSrb36gc4YhfmmjYnnsbZR6KGGwZDDhdI9xfG:|aYOgbY5lfWO2aX;u NYPFV414OjJ{MU[xOVg>
Molt4-hyg M3rYUGFxd3C2b4Ppd{BCe3OjeR?= MnTnNVDPxE1? NGP5fpkxNjWq Ml24Zoxw[2u|IH\hdo5me2:uLXnu[JVk\WRiY3HzdIF{\S1|LXzpb4Uh[WO2aY\peJk> MVWyOlI4PThzMR?=
HeLa MVvBdI9xfG:|aYOgRZN{[Xl? MW[xNO69VQ>? Mni3NE42cA>? Mm\HbY5pcWKrdIOgZZBweHSxc3nzJIlv\HWlZXSgZpkhfGinIHPvcYJqdmWmIITy[YF1dWWwdDD3bZRpKGexbXnzbY4hViCjbnSgWHJCUUx? MV6yNlE4QTZ4MR?=
Jurkat T MYjBdI9xfG:|aYOgRZN{[Xl? M1O2c|Mx|ryP MnHGNE42cA>? NXTJ[moxTE2VTx?= MWricI9kc3NidHjlJJpqemGvLXnu[JVk\WRiYYDvdJRwe2m| NYq5OnFKOjJzNUm4PVg>
Neutrophil NGL0cnhCeG:ydH;zbZMhSXO|YYm= NGTnbmUzOM7:TR?= M1f0XlAvPWh? NX;LdVM{[XS2ZX71ZZRmeyC2aHWgdJJwNWGyb4D0c5Rq[yCnZn\lZ5Qhd2ZiTXHSNS=> MXyyOlE6Pjh2NB?=
HCT116 NVvocZNtSXCxcITvd4l{KEG|c3H5 M13GZVUxyqEQvF2= NFWyOJkzcA>? MWHy[ZZmenOnczDzfY5memerc4TpZ{BieG:ydH;zbZMh\W[oZXP0d{Bw\iClZXzlZ495cWJiYX7kJG5RSy1zNtMg MlX1NlIyPTl5NUK=
MDA-MB-231  NXnmSItFSXCxcITvd4l{KEG|c3H5 M3TOclIvPS15LkZOwG0> MoDkNog> MXPpcohq[mm2czD0bIUh[2WubDDk[YF1cCCxZjDNSGEuVUJvMkOxJINmdGy|IHnu[JVk\WRiYomgV2RVKGmwIHGgZ49v[2WwdILheIlwdiCmZYDlcoRmdnRibXHucoVz MkjNNlIyOTV3Mk[=
LNCaP NHT1N5VCeG:ydH;zbZMhSXO|YYm= MV:0NO69VQ>? MU[ybC=> MmfWbY5pcWKrdIOgZpV1\WmwIHnu[JVk\WRiY3XscEBieG:ydH;zbZM> MkW0NlIyOTR5NkS=
MB231 NHG0PVZCeG:ydH;zbZMhSXO|YYm= MWSxNFDPxE1? NHK3XFcycA>? NFPyT3BFVVOR Ml;XZYJzd2ejdHXzJJRp\SCrbnT1Z5Rqd25ib3[gZ4VtdCCmZXH0bEBjgSCZRVWxJIlvcGmkaYTpc44tKFSUQVnMJJRz\WG2bXXueEwh[W6mIITo[UBkd22kaX7heIlwdg>? M3:yS|IzOTF{OUSw
HCC38  MYPBdI9xfG:|aYOgRZN{[Xl? MUixNFDPxE1? Mn\RNYg> MX;EUXNQ NXXncmhS[WK{b3fheIV{KHSqZTDpcoR2[3Srb36gc4Yh[2WubDDk[YF1cCCkeTDXSWUyKGmwaHnibZRqd25uIGTSRWlNKHS{ZXH0cYVvfCxiYX7kJJRp\SClb33ibY5ifGmxbh?= NX7zW3NTOjJzMUK5OFA>
MDA-MB231 M1PPemFxd3C2b4Ppd{BCe3OjeR?= NEHUe3c2OMLizszN NGP6U3MzPGh? NEi1fGNFVVOR Mn3SZYJzd2ejdHXzJIN2emO3bXnuMYlv\HWlZXSgZ4VtdCCmZXH0bC=> MmqzNlIyODF|M{W=
LNCaP NGPBSWpCeG:ydH;zbZMhSXO|YYm= MlHaOVDDqM7:TR?= MYmyOIg> Mn;OSG1UVw>? MmLDZYJzd2ejdHXzJIN2emO3bXnuMYlv\HWlZXSgZ4VtdCCmZXH0bC=> M1TyUVIzOTBzM{O1
HCT116 MXfBdI9xfG:|aYOgRZN{[Xl? MkS1OVDDqM7:TR?= NXSyU2kzOjSq NH\yT|BFVVOR MULhZpJw\2G2ZYOgZ5Vz[3WvaX6tbY5lfWOnZDDj[YxtKGSnYYTo NV7pSYZnOjJzMEGzN|U>
Ishikawa  Moq5RZBweHSxc3nzJGF{e2G7 MV:yOe69VQ>? MXmyOIg> Mn\NdoVlfWOnczDj[YxtKGSnYYToJIFv\CCjcH;weI9{cXNiaX7keYNm\CCkeTDCZYYhSTF? NEj6cnMzOjB6OEmxPC=>
 YD-8  NHnL[lBCeG:ydH;zbZMhSXO|YYm= M2jWclExOM7:TR?= Mlr1NYg> MojrbY5pcWKrdIOgVGxGVy2rbnT1Z4VlKGGyb4D0c5Nqew>? MYmyNlA5PjF6Mx?=
eosinophil  NF7PZ5NCeG:ydH;zbZMhSXO|YYm= NWnUVFVsQTEQvF2= MVWyOIg> M1O0c4lvcGmkaYTzJIFxd3C2b4Ppd{BqdmS3Y3XkJIJ6KE[jczDhcpRq[m:medMg MlXKNlIxPzl|M{S=
L929 MlzBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlTaNk42|ryP MX[yOIg> NFm3dI1qdmirYnn0d{B1cGViZYjwdoV{e2mxbjDv[kBxNXB|ODDhcoQhVkZvzsrCJJRwKGG3Z33lcpQhXE6IzsGtbY5lfWOnZDDu[YNzd3C2b4Ppd{BidmRiYYX0c5Bp[We7 MUSyNlAzPzB7Nx?=
YD-8  NV7KSXN1SXCxcITvd4l{KEG|c3H5 NF3QepcyODEQvF2= M{Xrc|Fp M4KyT4Jtd2OtczD0bIUhT1NvSFPsMYlv\HWlZXSgZZBweHSxc3nz NGrPSHIzOjB{MEC3PC=>
HBx NIHS[2lCeG:ydH;zbZMhSXO|YYm= NG\FPIYzPc7:TR?= MXW0PIg> MojISG1UVw>? Mm\tdoVlfWOnZDDj[YxtKGSnYYToJIlv\HWlZXSgZpkhOy2PQR?= NWTKVYw{OjJyMkCwO|g>
U937  MmPxRZBweHSxc3nzJGF{e2G7 Mlq4OVDDqM7:TR?= NVvMS3BGOWh? M1rzNYlvcGmkaYTzJGhHNWmwZIXj[YQh[XCxcITvd4l{yqB? NIXscnQzOTl7OEezNS=>
HL60 NFXodIxCeG:ydH;zbZMhSXO|YYm= Mn7nOFDPxE1? NUTuWHVpPDCvaX6= NGHqb2pFVVOR Ml7VZoxw[2u|IFLOSGMh[2:vcH;1coR{KGmwZIXj[UBmgHCxc4Xy[UBw\iCyaH;zdIhifGmmeXzz[ZJqdmViYX7kJGRPSSCocnHncYVvfGG2aX;u M4Dl[lIyQTh|Mkm2
M-14 NH7UXWNCeG:ydH;zbZMhSXO|YYm= M{TneVI2|ryP NFzJfnIxNjWq NEPyeFLDqGmwaHnibZR{KGKxdHigeIhmKGO{dXTlJIV5fHKjY4StJIFv\CClb33wc5Vv\C2rbnT1Z4VlKGGyb4D0c5Nqew>? NXPodGNpOjF7NUS5OVk>
SK-BR-3 Mn6yRZBweHSxc3nzJGF{e2G7 NHLOSWs2OMLizszN M4XkUVJp NF7t[GNjdG:la4OgZZBweHSxdHnjJGRPSSCocnHncYVvfGG2aX;uJIlv\HWlZXSgZpkh[2:vYnnuZZRqd25ib3[gV20uOTZ2IHHu[EBz[WSrYYTpc44> MlzRNlE6ODF|OE[=
MDA-MB-468 M{fUSGFxd3C2b4Ppd{BCe3OjeR?= M3K0elUxyqEQvF2= M2nzS|Jp NFK2UXFjdG:la4OgZZBweHSxdHnjJGRPSSCocnHncYVvfGG2aX;uJIlv\HWlZXSgZpkh[2:vYnnuZZRqd25ib3[gV20uOTZ2IHHu[EBz[WSrYYTpc44> NVSwem9JOjF7MEGzPFY>

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
IRF-1 / p-STAT1 / cleaved PARP1 / cleaved-caspase3; 

PubMed: 27191889     


With the addition of Z-VAD-FMK, levels of cleaved Caspase-3 and PARP1 were decreased.

Beclin1 / Atg5 / Atg7 / LC-3I / LC-3II; 

PubMed: 27191889     


Levels of Beclin1, Atg5, Atg7 and LC3-II were decreased after IFN-γ stimulation. However, when IFN-γ was combined with the caspase inhibitor, levels of Beclin1, Atg5, Atg7 and LC3-II were not decreased as determined by the Western Blot test. 

p23 / Hsp90 / hTRET / MMP2; 

PubMed: 19740745     


Expression of Hsp90 client proteins during cell death. HeLa cells were preincubated with z-VAD-fmk (100 μM) for 1 h and exposed to various concentrations of tunicamycin (Tu, in μM) for 24 h. Cell extracts were prepared and analyzed by Western blotting. β-Actin was used as the loading control.

cyto C; 

PubMed: 17301139     


z-VAD-fmk did not inhibit cytochrome c release in RRV-infected MA104 cells (RRV: rhesus rotavirus). Mock- and RRV-infected MA104 cells either were not pretreated or were pretreated with 100 μM z-VAD-fmk for 2 h before RRV infection, and treatment was continued during infection. Fourteen hours after RRV infection, the cytosolic and heavy-membrane fractions were assayed for cytochrome c by Western blotting. Mock-infected MA104 cells were used as negative controls. Cox IV and tubulin were used as protein loading controls for the heavy-membrane and cytosolic fractions, respectively. Positions of molecular weight markers are indicated on the left.

27191889 19740745 17301139
Growth inhibition assay
Cell viability; 

PubMed: 12522090     


Inhibition of magnolol-induced apoptotic cell death by z-VAD-fmk. CH27 cells were treated with cell permeable broad-spectrum caspase inhibitor (z-VAD-fmk) 2 h prior to 80 μm magnolol treatment. Cell viability was estimated. ***P<0.001, compared with the 80 μM magnolol-treated group. 

12522090
Immunofluorescence
cytochrome c ; 

PubMed: 11726499     


Immunolocalization of Smac/DIABLO and cytochrome c in HeLa cells. (A-C) Viable (non-apoptotic) HeLa cells were stained with antibodies to cytochrome c (green) and Smac/DIABLO (red) as indicated. Note that both proteins clearly co-localize within punctate, mitochondrial structures. (D–F) HeLa cells, pre-incubated with z-VAD-fmk (100 µM), were UV-irradiated followed by further incubation for 8 h. Note the cells where cytochrome c has exited mitochondria and can be seen in a diffuse pattern throughout the cell, including the nucleus (white arrows). In the latter case, note the retention of Smac/DIABLO in punctate mitochondrial structures within the cytoplasm. (G-I) HeLa cells, pre-incubated with z-VAD-fmk (100 µM), were then treated with 10 µM actinomycin D for 8 h. Once again note the retention of Smac/DIABLO in mitochondrial structures. (J-L) HeLa cells were treated as described in (G-I). A close-up of a single cell that has undergone mitochondrial cytochrome c release, but where Smac/DIABLO is retained within mitochondria, is shown.

Smac/DIABLO; 

PubMed: 11726499     


Immunolocalization of Smac/DIABLO and cytochrome c in HeLa cells. (A-C) Viable (non-apoptotic) HeLa cells were stained with antibodies to cytochrome c (green) and Smac/DIABLO (red) as indicated. Note that both proteins clearly co-localize within punctate, mitochondrial structures. (D–F) HeLa cells, pre-incubated with z-VAD-fmk (100 µM), were UV-irradiated followed by further incubation for 8 h. Note the cells where cytochrome c has exited mitochondria and can be seen in a diffuse pattern throughout the cell, including the nucleus (white arrows). In the latter case, note the retention of Smac/DIABLO in punctate mitochondrial structures within the cytoplasm. (G-I) HeLa cells, pre-incubated with z-VAD-fmk (100 µM), were then treated with 10 µM actinomycin D for 8 h. Once again note the retention of Smac/DIABLO in mitochondrial structures. (J-L) HeLa cells were treated as described in (G-I). A close-up of a single cell that has undergone mitochondrial cytochrome c release, but where Smac/DIABLO is retained within mitochondria, is shown.

Endo G; 

PubMed: 12941691     


GFP-Bax expression and immunostaining of EndoG together with nuclear Hoechst staining in HeLa cells 18 h after transient transfection with a vector encoding GFP-Bax in the absence or in the presence of the caspase inhibitor z-VAD-fmk (100 μM). 

AIF; 

PubMed: 12941691     


GFP-Bax expression and immunostaining of AIF together with nuclear Hoechst staining in HeLa cells 18 h after transient transfection with a vector encoding GFP-Bax in the absence or in the presence of the caspase inhibitor z-VAD-fmk (100 μM). 

11726499 12941691
ELISA
IL-1β; 

PubMed: 26254306     


Cell-free medium supernatants were harvested at 5 h. IL-1β levels were measured by ELISA. Z-VAD-FMK was used as a positive control. Bars represent means ± sem of pooled results from 3 experiments performed in triplicate at different times.

26254306
In vivo In vivo Z-VAD-FMK administration has been shown previously to be nontoxic and to prevent apoptosis in animal models. Intraperitoneal HK-GBS injection leads to preterm delivery, and pretreatment with Z-VAD-FMK delays preterm delivery in mice. In OVA-sensitized mice,treatment of z-VAD-fmk inhibits allergen-induced leukocyte infiltration. Systemic injection of the pan-caspase inhibitor z-VAD-fmk immediately before OVA challenge reduced inflammatory cell accumulation, mucus hypersecretion, and Th2 cytokine release in OVA-sensitized/challenged mice. Treatment with z-VAD-fmk blocked terminal differentiation of lens epithelial cells and keratinocytes, the differentiation of monocytes into macrophages, and the differentiation of erythroid progenitors. z-VAD-fmk attenuated allergen-induced airway inflammation and hyperreactivity. Treatment with z-VAD-fmk in vivo also prevented subsequent T cell activation ex vivo[7].

Protocol

Cell Research:

[6]

- Collapse
  • Cell lines: human granulosa cell lines (GC1a, HGL5, COV434)
  • Concentrations: 50 μM
  • Incubation Time: 48 h
  • Method:

    To validate the efficacy of Z-VAD-FMK, three human granulosa cell lines (GC1a, HGL5, COV434) were treated for 48 h with etoposide (50 μg/ml) and/or Z-VAD-FMK (50 μM) under normoxic conditions. To mimic the ischemic phase that occurs after ovarian fragment transplantation, cells were cultured without serum under hypoxia (1 % O2) and treated with Z-VAD-FMK. The metabolic activity of the cells was evaluated by WST-1 assay. Cell viability was determined by FACS analyses. The expression of apoptosis-related molecules was assessed by RT-qPCR and Western blot analyses.


    (Only for Reference)
Animal Research:

[7]

- Collapse
  • Animal Models: CD1 mice
  • Dosages: 10 mg/kg
  • Administration: i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 93 mg/mL (198.93 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+35 %PEG 300+2%Tween 80+ddH2O
For best results, use promptly after mixing.
6mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 467.49
Formula

C22H30FN3O7

CAS No. 187389-52-2
Storage powder
in solvent
Synonyms N/A

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Can you suggest an in vivo formulation of S7023 for animal studies?

  • Answer:

    For in vivo study of S7023, The IP formulation is 2% DMSO+35 % PEG 300+2% Tween 80+ddH2O up to 6 mg/ml. The gavage formula is 1%CMC-Na up to 30 mg/ml (suspensions).

  • Question 2:

    What is difference between S7023 & S8102?

  • Answer:

    Unlike S7023, S8102 does not require pretreatment with esterase for in vitro studies. This information was cited from the article: https://www.ncbi.nlm.nih.gov/pubmed/16973565.

Caspase Signaling Pathway Map

Related Caspase Products

Tags: buy Z-VAD-FMK | Z-VAD-FMK supplier | purchase Z-VAD-FMK | Z-VAD-FMK cost | Z-VAD-FMK manufacturer | order Z-VAD-FMK | Z-VAD-FMK distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID